Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
I-57: Treatment of Primary HIV Infection with Zidovudine, Lamivudine and Indinavir: A Case-Control Study

September 25, 1998

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

More data is accumulating that initiation of combination antiretroviral therapy may have a greater impact on preservation of immune function when used earlier in the course of disease, and CDC guidelines for the use of combination therapy following high risk exposure is derived from the knowledge that productive infection may be prevented when the amount of virus is low and there is little provirus (viral RNA converted to DNA and inserted into the host genome). Berrey and colleagues presented data comparing the virologic and clinical course of 70 patients with primary HIV infection who were evaluated within 90 days of symptom onset. As this study included individuals evaluated between 1993 and 1997, only the last 20 patients evaluated received combination therapy, consistent with the bias towards treatment in this setting during the last two years.

Twenty patients were immediately treated with AZT, 3TC, indinavir, while the first 50 received no therapy. Comparing the two groups at enrollment, both exhibited similar viral load and immune parameters (145,864 copies/ml; mean 697 CD4 cells/dl in treated vs. 119,769 copies/ml; mean 624 CD4 cells/dl in untreated).

Tolerability to the combination therapy appeared as follows:

  • 9/20 required change from AZT to D4T due to anemia or nausea and vomiting
  • 2/20 had grade 3 or 4 increase in bilirubin or increase transaminase (pt had Hepatitis A)
  • 4/8 had triglycerides > 200 at 6-18 months following therapy initiation
  • 16/20 remained on treatment at 12 months
  • 15/20 on treatment at 18 months

All treated patients achieved undetectable levels of HIV RNA (<500 copies) by week 12, and all patients remaining on therapy by week 24 were undetectable at <20 copies/ml. During the 18 months of follow up, the treated group gained an average of 8.8 CD4 cells per month while the untreated group lost an average of 13.8 CD4 cells, month (p=0.0018). Furthermore none of the treated patients developed any major or minor complications of HIV, while in the untreated group 6 developed oral candida, 6 demonstrated oral hairy leukoplakia, 3 experienced peripheral neuropathy and one had esophageal candidiasis. Although this study demonstrates clinical benefit from early initiation of combination therapy, it will require ongoing follow up to determine whether clinical benefits will be sustained.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Reference

Abstract: Treatment of Primary HIV Infection with Zidovudine, Lamivudine and Indinavir: A Case-Control Study
Authored by: M. M. Berrey et al

See Also
More Research on Primary (Acute) HIV Infection



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement